Immune checkpoint inhibitors transformed melanoma treatment. They also leave a large share of patients behind, and figuring out what to do for those patients is the central unsolved problem in the field.
UCLA researchers have received a five-year, $3.9 million grant from the National Cancer Institute to work on it. The award goes to Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, according to UCLA Health. She is also a member of the UCLA Broad Stem Cell Research Center and the UCLA Parker Institute for Cancer Immunotherapy.
